You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Litigation Details for Halozyme, Inc. v. Lee (E.D. Va. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Halozyme, Inc. v. Lee (E.D. Va. 2016)

Docket ⤷  Try a Trial Date Filed 2016-12-18
Court District Court, E.D. Virginia Date Terminated 2018-07-31
Cause 35:145 Patent Non-Infringement- Patent Applicant is Dissatisfied with PTO Decision Assigned To Claude M. Hilton
Jury Demand None Referred To John F. Anderson
Parties HALOZYME, INC.
Patents 7,767,429; 7,829,081; 7,846,431; 7,871,607
Attorneys Dennis Carl Barghaan , Jr.
Firms McDermott Will & Emery LLP - DC
Link to Docket External link to docket
Biologic Drugs cited in Halozyme, Inc. v. Lee

The biologic drugs covered by the patents cited in this case are ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , and ⤷  Try a Trial .

Details for Halozyme, Inc. v. Lee (E.D. Va. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-12-18 1 non-statutory obviousness-type double patenting over U.S. Patent Nos. 7,767,429 (claims 9 and 10), 7,846,431 …to receive a patent against Defendant, MICHELLE K, LEE, Director, United States Patent and Trademark ….S. Patent No. 5,766,897, issued June 16, 1998 (“Braxton”); and (c) Thompson et al., U.S. Patent No. …Property ) and Director of the United States Patent and ) Trademark Office, …pursuant to 35 U.S.C. § 145 by the assignee of U.S. Patent Application Serial No. 11/238,171 (“the ’171 Application External link to document
2017-11-12 143 statutory obviousness-type double patenting over U.S. Patent Nos. 7,767,429 (Claims 9 and 10), 7,846,431…of a patent . . . by prohibiting the issuance of the claims in a second patent not patentably distinct…the applicant for patent or (2) a patent granted on an application for patent by another filed…Claim 264 and the ‘429 Patent Claims 9 and 10 Are Patentably Distinct. ...........… The Pending Claims are patently distinct from Claim 6 of the ’081 Patent. [Flamion Test.] External link to document
2018-07-31 173 of U.S. Patent No. 7,767,429 ("the M29 patent") in…seeking reversal of a patent rejection decision issued by the United States Patent and Trademark Office…challenging a final decision issued by the USPTO's Patent Trial and Appeal Board (the "Board")…affirmed the rejections of claims in U.S. Patent Application 11/238,171 ("…2016 31 July 2018 1:16-cv-01580 830 Patent None District Court, E.D. Virginia External link to document
2018-10-23 186 U.S. Patent No. 7,767,429 ("the M29 patent") in view of the U.S. Patent No. …lancu's. Under Secretary of the United States Patent and Trademark Office ("USPTO"), motion…challenging a final decision issued by the USPTC s Patent Trial and Appeal Board (the ^'Board"…the rejections of claims in U.S. Patent Application 11/238,171 ("the … 5,766,897 ("Braxton") and U.S. Patent No. 6,552,170 ("Thompson" External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.